ANA NLP Poster

October 17, 2016 Kerry Rowe

ana-2016-poster-final

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

ANA NLP Poster

Related Posts

Prana Alzheimer’s disease data features at world leading conference

World leader in movement disorders Professor Ira Shoulson joins Prana board

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development